AgingResearch.NewsJoin free

AOP Health

CompanyAustria

AOP Health develops one asset, approved (landiolol in supraventricular tachycardia). Mostly small molecule acting on ADRB1; based in Austria.

1
Asset
Furthest stage
Approved
0
Trials
1
Signal

Pipeline

1

  • landiolol

    Selectively blocks beta-1 adrenergic receptors to rapidly reduce ventricular rate.

    Approved, Small molecule, ADRB1, supraventricular tachycardia

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Signals1
  • Similar companies1

Intelligence